Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 1/2018

Open Access 01-03-2018 | Case Report

Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report

Authors: Tamim Alsuliman, Kaiss Lassoued, Maifa Belghoul, Karima Debbache, Bachra Choufi

Published in: Dermatology and Therapy | Issue 1/2018

Login to get access

Abstract

Introduction

Pentostatin (2′-deoxycoformycin) and cladribine (2-chlorodeoxyadenosine) are adenosine analogues widely used to treat lymphoid malignancies, mainly hairy cell leukemia (HCL). Oral or parenteral adenosine analogues have been also used as immunomodulatory agents in multiple sclerosis and in acute graft-versus-host disease.

Case Report

Here, we report the case of a 43-year-old patient with a history of extensive psoriasis who later developed HCL.

Results

The patient had achieved complete remission of both psoriasis and HCL after receiving intravenous infusions of pentostatin. It is worth noting that cladribine has already been reported to treat plaque psoriasis lesions in two patients with HCL and in a third patient with gastric marginal zone B cell lymphoma [1].

Conclusion

We believe that adenosine analogues constitute a promising therapeutic option for moderate to severe psoriasis, especially for severe and refractory psoriasis, as well as for patients with adjacent lymphoid malignancies.
Literature
1.
Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–73.CrossRefPubMed
2.
3.
Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;33(Suppl 93):S2–6.PubMed
4.
Gaspari AA, Tyring S. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther. 2015;28:179–93.CrossRefPubMedPubMedCentral
5.
Chiricozzi A, Saraceno R, Novelli L, et al. Small molecules and antibodies for the treatment of psoriasis: a patent review (2010–2015). Expert Opin Ther Pat. 2016;13:1–10.
6.
Kwatra SG, Dabade TS, Gustafson CJ, Feldman SRJ. JAK inhibitors in psoriasis: a promising new treatment modality. J Drugs Dermatol. 2012;11:913–8.PubMed
7.
Summers TA, Jaffe ES. Hairy cell leukemia diagnostic criteria and differential diagnosis. Leuk Lymphoma. 2011;52(Suppl 2):6–10.CrossRefPubMed
8.
Grever MR, Blachly JS, Andriotos LA. Hairy cell leukemia: update on molecule profiling and therapeutic advances. Blood Rev. 2014;28:197–203.CrossRefPubMed
9.
Johnston JB. Mechanism of action of pentostatin and cladribine in hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl2):43–5.CrossRefPubMed
10.
Korsen M, Bragado Alonso S, Peix L, et al. Cladribine exposure results in a sustained modulation of the cytokine response in human peripheral blood mononuclear cells. PLoS One. 2015;10:e0129182.CrossRefPubMedPubMedCentral
11.
Jacobsohn DA, Gilman AL, Rademaker A, et al. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a pediatric blood and marrow transplant consortium study. Blood. 2009;114:4354–60.CrossRefPubMed
12.
Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–26.CrossRefPubMed
13.
14.
Zinzani PL, Ricci P, Bendandi M, Tura S. 2-Chlorodeoxyadenosine in psoriasis treatment. Ann Oncol. 1995;6:509.CrossRefPubMed
15.
Ilyas W, Myers D, Mann R, Seraly MP. Remission of psoriasis after treatment with interferon-alfa and 2-chlordeoxyadenosine for hairy cell leukemia. J Am Acad Dermatol. 1999;41:316–8.CrossRefPubMed
16.
Valencak J, Trautinger F, Fiebiger WC, Raderer M. Complete remission of chronic plaque psoriasis and gastric marginal zone B-cell lymphoma of MALT type after treatment with 2-chlorodeoxyadenosine. Ann Hematol. 2002;81:662–5.CrossRefPubMed
17.
18.
Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Hematol Am Soc Hematol Educ Progr. 2015;2015:529–44.
19.
20.
Di Costanzo L, Ayala F, Megna M, Gaudiello F, Patrì A, Balato N. The risk of herpes zoster in the anti-TNF-α era: a case report and review of the literature. J Dermatol Case Rep. 2013;7(1):1–4.CrossRefPubMedPubMedCentral
21.
Metadata
Title
Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report
Authors
Tamim Alsuliman
Kaiss Lassoued
Maifa Belghoul
Karima Debbache
Bachra Choufi
Publication date
01-03-2018
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 1/2018
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-017-0216-z

Other articles of this Issue 1/2018

Dermatology and Therapy 1/2018 Go to the issue

Original Research

Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies

Brief Report

Daylight Photodynamic Therapy Versus 5-Fluorouracil for the Treatment of Actinic Keratosis: A Case Series

Original Research

A Qualitative Investigation of the Impact of Acne on Health-Related Quality of Life (HRQL): Development of a Conceptual Model

Case Report

Dapsone for Recalcitrant Eosinophilic Annular Erythema: A Case Report and Literature Review

Commentary

Neuromodulation in Inflammatory Skin Disease

Original Research

Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits